Clinical Trial

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-23
notable Enrollment reduced: 39 -> 26 participants 2026-05-23
notable Trial sites reduced: 43 -> 26 locations 2026-05-23
notable Primary completion moved earlier: 2026-12-23 -> 2026-04-21 2026-05-23
minor Completion moved earlier: 2027-05-12 -> 2026-09-09 2026-05-23
Trial Details
NCT Number NCT05668741
Lead Sponsor Vertex Pharmaceuticals Incorporated
Collaborators: Moderna, Inc
Conditions Cystic Fibrosis
Enrollment 26 participants
Start Date 2023-02-27
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-09-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-22